Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Benza, M. Gomberg-Maitland, Dave Miller, A. Frost, R. Frantz, A. Foreman, D. Badesch, M. McGoon (2012)
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.Chest, 141 2
M. Humbert, O. Sitbon, A. Yaici, D. Montani, D. O’Callaghan, X. Jaïs, F. Parent, L. Savale, D. Natali, S. Günther, A. Chaouat, F. Chabot, J. Cordier, G. Habib, V. Gressin, Z. Jing, R. Souza, G. Simonneau (2010)
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertensionEuropean Respiratory Journal, 36
JP Burke, E Hunsche, E Régulier, M Nagao, P Buzinec, W Drake (2015)
Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database studyAm J Manag Care, 21
RL Benza, DP Miller, M Gomberg-Maitland (2010)
Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL)Circulation, 122
A. Ogbomo, Y. Tsang, F. Kariburyo, Wan-Lun Tsai, S. Panjabi (2021)
Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial HypertensionPulmonary Therapy, 7
Vallerie McLaughlin, M. Hoeper, R. Channick, Kelly Chin, M. Delcroix, S. Gaine, H. Ghofrani, P. Jansa, Irene Lang, S. Mehta, T. Pulido, B. Sastry, G. Simonneau, O. Sitbon, R. Souza, A. Torbicki, V. Tapson, L. Perchenet, R. Preiss, P. Verweij, L. Rubin, N. Galiè (2018)
Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality.Journal of the American College of Cardiology, 71 7
AC Lajoie, G Lauzière, J-C Lega (2016)
Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysisLancet Respir Med, 4
N. Galiè, M. Humbert, J. Vachiéry, S. Gibbs, I. Lang, A. Torbicki, G. Simonneau, A. Peacock, A. Noordegraaf, M. Beghetti, A. Ghofrani, M. Sánchez, G. Hansmann, W. Klepetko, P. Lancellotti, M. Matucci, T. McDonagh, L. Pierard, P. Trindade, M. Zompatori, M. Hoeper (2015)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 46
O Sitbon, R Channick, KM Chin (2015)
Selexipag for the treatment of pulmonary arterial hypertensionN Engl J Med, 373
N. Kirson, H. Birnbaum, J. Ivanova, T. Waldman, V. Joish, T. Williamson (2011)
Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured populationApplied Health Economics and Health Policy, 9
M. Gauthier-Loiselle, Y. Tsang, P. Lefebvre, P. Agron, Jimmy Royer, Karimah Lynum, Lucas Bennett, S. Panjabi (2022)
Development and evaluation of a predictive algorithm for unsatisfactory response among patients with pulmonary arterial hypertension using health insurance claims dataCurrent Medical Research and Opinion, 38
S. Studer, M. Hull, J. Pruett, C. Elliott, Y. Tsang, W. Drake (2019)
Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial HypertensionPulmonary Therapy, 6
C. Burger, Pamela Long, Monarch Shah, M. McGoon, Dave Miller, A. Romero, W. Benton, R. Safford (2014)
Characterization of First-Time Hospitalizations in Patients With Newly Diagnosed Pulmonary Arterial Hypertension in the REVEAL RegistryChest, 146
JD Lee, CD Burger, GB Delossantos (2020)
A survey-based estimate of COVID-19 incidence and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension and impact on the process of careAnn Am Thorac Soc, 17
JB Segal, H-Y Chang, Y Du, JD Walston, MC Carlson, R Varadhan (2017)
Development of a claims-based frailty indicator anchored to a well-established frailty phenotypeMed Care, 55
M. Humbert, J. Coghlan, D. Khanna (2012)
Early detection and management of pulmonary arterial hypertensionEuropean Respiratory Review, 21
A. Frost, D. Badesch, Dave Miller, R. Benza, Leslie Meltzer, M. McGoon (2013)
Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.Chest, 144 5
B. Fox, O. Shtraichman, D. Langleben, A. Shimony, M. Kramer (2016)
Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis.The Canadian journal of cardiology, 32 12
Wai-ting Lee, Y. Ling, K. Sheares, J. Pepke-Zaba, A. Peacock, Martin Johnson (2012)
Predicting survival in pulmonary arterial hypertension in the UKEuropean Respiratory Journal, 40
TM Cascino, AA Desai, Y Kanthi (2021)
At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular diseaseCurr Opin Pulm Med, 27
R. Benza, M. Gomberg-Maitland, C. Elliott, H. Farber, A. Foreman, A. Frost, M. McGoon, D. Pasta, M. Selej, C. Burger, R. Frantz (2019)
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.Chest
J. Badlam, T. Bull (2017)
Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunitiesTherapeutic Advances in Chronic Disease, 8
N. Galiè, R. Channick, R. Frantz, E. Grünig, Z. Jing, O. Moiseeva, I. Preston, T. Pulido, Z. Safdar, Yuichi Tamura, V. McLaughlin (2019)
Risk stratification and medical therapy of pulmonary arterial hypertensionThe European Respiratory Journal, 53
CD Burger, AB Ozbay, HM Lazarus (2018)
Treatment patterns and associated health care costs before and after treatment initiation among pulmonary arterial hypertension patients in the United StatesJ Manag Care Spec Pharm, 24
A. Martirosov, Zachary Smith, L. Hencken, Nancy Macdonald, K. Griebe, Patricia Fantuz, G. Grafton, S. Hegab, R. Ismail, Barb Jackson, B. Kelly, M. Miller, R. Awdish (2020)
Improving transitions of care for critically ill adult patients on pulmonary arterial hypertension medications.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 77 12
S. Studer, M. Hull, J. Pruett, E. Koep, Y. Tsang, W. Drake (2018)
Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US databasePulmonary Circulation, 9
I. Farmakis, P. Karyofyllis, F. Frantzeskaki, E. Demerouti, A. Anthi, A. Arvanitaki, G. Pitsiou, K. Naka, A. Bechlioulis, A. Thomaidi, A. Avgeropoulou, S. Brili, I. Mitrouska, A. Manginas, S. Orfanos, I. Tsangaris, G. Giannakoulas (2021)
Incidence and outcomes of COVID-19 in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)Hellenic Journal of Cardiology, 64
E. Bergot, L. Léotoing, H. Bendjenana, C. Tournier, A. Vainchtock, G. Nachbaur, M. Humbert (2019)
Hospital burden of pulmonary arterial hypertension in FrancePLoS ONE, 14
IntroductionUS claims-based analyses emphasize the substantial hospitalization burden of patients with pulmonary arterial hypertension (PAH) and the significant need for improved monitoring and more timely interventions. A claims-based predictive model may be useful to assist healthcare providers and payers in identifying patients with PAH at increased hospitalization risk. To address this aim, we constructed statistical models using baseline patient variables available in administrative healthcare claims to predict patients’ risk for all-cause and PH-related hospitalization within 1 year of initiating ≥ 1 PAH indicated medication.MethodsAdult patients with PAH who newly initiated ≥ 1 PAH indicated medication were selected from the MarketScan Commercial and Medicare Supplemental databases (January 1, 2009–January 31, 2019). Cox regression models were built with a randomly selected training set and evaluated using a validation set of remaining patients. Predictive variables for the models were selected in three steps: clinical knowledge, univariate analysis, and backward stepwise selection.ResultsWithin 1 year of initiating ≥ 1 PAH indicated medication, 1502/3872 (38.8%) had an all-cause hospitalization and 950/3872 (24.5%) had a pulmonary hypertension (PH)-related hospitalization. Predictive risk factors for all-cause hospitalization were Quan–Charlson Comorbidity Index (CCI) score 2–3 [hazard ratio (HR) 1.229; P = 0.038] and ≥ 4 (HR 1.531; P < 0.001), claims-based frailty index (CFI) score > 1 (highest frailty level; HR 1.301; P = 0.018), hemoptysis (HR 1.254; P = 0.016), malaise/fatigue (HR 1.150; P = 0.037), history of PH-related hospitalization (HR 1.171; P = 0.011), non-PH-related ER visit (HR 1.713; P = 0.014), and higher non-PH-related outpatient visit cost (HR 1.069; P < 0.001). Predictive risk factors for PH-related hospitalization were female sex (HR 1.264; P = 0.004), Quan-CCI score ≥ 4 (HR 1.408; P = 0.008), portal hypertension (HR 1.565; P = 0.019), CFI score > 1 (HR 1.522; P = 0.002), dyspnea (HR 1.259; P = 0.023), and history of PH-related hospitalization (HR 1.273; P = 0.002).ConclusionsThe US claims-based predictive models showed acceptable performance to predict 1-year hospitalization among patients with PAH.
Advances in Therapy – Springer Journals
Published: Apr 6, 2023
Keywords: Hospitalization; Healthcare resource utilization; Predictive risk factors; Patient characteristics; Pulmonary arterial hypertension
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.